FI20116181A - New therapeutic vectors - Google Patents

New therapeutic vectors Download PDF

Info

Publication number
FI20116181A
FI20116181A FI20116181A FI20116181A FI20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A
Authority
FI
Finland
Prior art keywords
new therapeutic
therapeutic vectors
vectors
new
Prior art date
Application number
FI20116181A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI123955B (en
Inventor
Tuuli Ranki
Akseli Hemminki
Vincenzo Cerullo
Anniina Koski
Original Assignee
Oncos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncos Therapeutics Ltd filed Critical Oncos Therapeutics Ltd
Priority to FI20116181 priority Critical
Priority to FI20116181A priority patent/FI123955B/en
Publication of FI20116181A publication Critical patent/FI20116181A/en
Application granted granted Critical
Publication of FI123955B publication Critical patent/FI123955B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material
    • C12N2710/10052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
FI20116181A 2011-11-25 2011-11-25 Oncolytic adenovirus FI123955B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20116181 2011-11-25
FI20116181A FI123955B (en) 2011-11-25 2011-11-25 Oncolytic adenovirus

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FI20116181A FI123955B (en) 2011-11-25 2011-11-25 Oncolytic adenovirus
EP12852023.6A EP2783005A4 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (ac]5) adenoviral vectors
PCT/FI2012/051162 WO2013076374A1 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (ac!5) adenoviral vectors
US14/359,141 US9410129B2 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (Ad5) adenoviral vectors
EP15186798.3A EP3006566A1 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (ac]5) adenoviral vectors
US14/866,582 US20160082100A1 (en) 2011-11-25 2015-09-25 RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS

Publications (2)

Publication Number Publication Date
FI20116181A true FI20116181A (en) 2013-05-26
FI123955B FI123955B (en) 2014-01-15

Family

ID=48469205

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20116181A FI123955B (en) 2011-11-25 2011-11-25 Oncolytic adenovirus

Country Status (4)

Country Link
US (2) US9410129B2 (en)
EP (2) EP2783005A4 (en)
FI (1) FI123955B (en)
WO (1) WO2013076374A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US20160143967A1 (en) * 2013-06-18 2016-05-26 Dnatrix, Inc. Treatment of brain cancer with oncolytic adenovirus
CN104328140B (en) * 2014-10-08 2018-06-05 兰州大学 A kind of high preferendum bladder cancer target tumor-killing adenovirus
CA3004048A1 (en) * 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
US10076562B2 (en) 2016-04-19 2018-09-18 The Board Of Regents Of The University Of Texas System Methods for treating plague
WO2018140970A1 (en) * 2017-01-30 2018-08-02 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
IL152420D0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
ES2304281B1 (en) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos for the treatment of cancer.
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
JP2012513209A (en) 2008-12-22 2012-06-14 オンコス セラピュティックス オサケ ユキチュア Oncolytic adenoviral vectors and related methods and uses
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
JO3257B1 (en) * 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators

Also Published As

Publication number Publication date
US9410129B2 (en) 2016-08-09
EP2783005A1 (en) 2014-10-01
WO2013076374A1 (en) 2013-05-30
FI123955B (en) 2014-01-15
US20160082100A1 (en) 2016-03-24
EP2783005A4 (en) 2015-07-22
US20150232811A1 (en) 2015-08-20
EP3006566A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
DK2771182T3 (en) Indkapslingsbarrierestak
BR112014005322A2 (en) Process
BR112013013311A2 (en) cytotoxicity-inducing therapeutic agent
BR112014008888A2 (en) Pyrrolobenzodiazepines
GB201212513D0 (en) Therapeutic agents
FR2976033B1 (en) Fixing devices
BR302012001691S1 (en) Eyeglass Configuration
DE112012000884A5 (en) execution
BR112013032558A2 (en) appliance
EP2673286A4 (en) Therapeutic compounds
PT2809657T (en) Novel therapeutic agents
BRDI7103675S (en) Cover configuration
FR2977794B3 (en) Massage tools
FI20110196A (en) Switch
FI20115945A0 (en) payment
BR112013033444A2 (en) wound therapy formulations
DK2776436T3 (en) New connections
FR2978019B1 (en) Improved shoe shoe
BR112014003334A2 (en) Cover
DE112012001607A5 (en) retractor
BR112014002553A2 (en) Device
DK3159459T1 (en) datacenter
DK2782555T3 (en) Blodpladelysatgel
BRDI7106545S (en) Configuration applied toy
BR112014016000A8 (en) process

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 123955

Country of ref document: FI

Kind code of ref document: B